SOURCE: Implant Sciences Corporation

Implant Sciences Corporation

July 23, 2012 09:53 ET

Implant Sciences Extends Global Distribution Network Into Switzerland

WILMINGTON, MA--(Marketwire - Jul 23, 2012) - Expanding both its global reach and sales of its new QS-B220 system, Implant Sciences Corporation (OTCQB: IMSC) (PINKSHEETS: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that it has added a new distributor in Switzerland. This is the Company's first distributor in that country. The new distributor has purchased a Quantum Sniffer™ QS-B220 system to use as a demonstration unit.

The QS-B220 is a desktop explosives and drugs trace detector that is currently being evaluated for certification by the U.S. Transportation Security Administration (TSA) for air cargo screening. Introduced last year, the system is already deployed in Europe, the Middle East, Asia, and the Americas.

"The QS-B220's ease of use, ability to clear rapidly after detection, and large color touch-screen are receiving growing attention from security professionals worldwide. Furthermore, in a world increasingly concerned about radiation safety, Implant Sciences' non-radioactive design is subject to far fewer regulations and restrictions than competing systems," stated Implant Sciences' Vice President of Global Sales and Marketing, Dr. Darryl Jones. "We see a bright future for the QS-B220, one that will only get brighter as we secure certifications from government regulatory agencies around the world."

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 desktop explosives and drugs trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risk that we will be required to repay all of our indebtedness to our secured lender, DMRJ Group, by September 30, 2012; that if we are unable to satisfy our obligations to DMRJ and to raise additional capital to fund operations, DMRJ may seize our assets and our business may fail; the risk that we continue to incur substantial operating losses and may never be profitable; the risk that liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; the risk that we may not be able to retain our management and key employees or to identify, hire and retain additional personnel as needed; the risks that we may not be able to enforce our patent and other intellectual property rights or operate without infringing on the proprietary rights of others; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:

    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    CEO
    978-752-1700
    Email Contact

    or

    Investor Contact:
    Laurel Moody
    646-810-0608
    Email Contact